Novo Nordisk: Stock Plunges, But It May Be Time To Load Up
Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Le Lézard19h
Unveiling Pharma Market Potential: DelveInsight's Strategic Insights into the Rapidly Expanding MASH Landscape in Asia
DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...
Investor's Business Daily on MSN3h
Stock Market Correction: Trump Tariffs Triggers Sell-Off Despite Tame Inflation: Weekly Review
The major indexes suffered another week of sharp losses as Trump tariffs ramped up, shrugging off tame inflation.
Fierce Pharma4h
Breaking down pharma’s fourth-quarter sales boom
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...